Steatosis predicts postoperative morbidity following hepatic resection for colorectal metastasis

British Journal of Surgery

Volumn 94, Issue 11, 2007, Pages 1395-1402

  Gomez, D ^a   Malik, H Z ^a   Bonney, G K ^a   Wong, V ^a   Toogood, G J ^a   Lodge, J P A ^a   Prasad, K R ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANESTHESIST; ARTICLE; BLOOD TRANSFUSION; CANCER PATIENT; COLORECTAL CANCER; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; FATTY LIVER; FEMALE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; LABORATORY TEST; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REFERENCE DATABASE; SURGICAL ANATOMY; SURGICAL MORTALITY; SURGICAL PATIENT;

ADULT; AGED; AGED, 80 AND OVER; BLOOD TRANSFUSION; BODY MASS INDEX; COLORECTAL NEOPLASMS; FATTY LIVER; HEPATECTOMY; HUMANS; LENGTH OF STAY; LIVER NEOPLASMS; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 36348974014     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.5820     Document Type: Article

References (50)

1. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002; 235: 759-766.
2. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239: 818-825.
3. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004; 240: 438-447.
4. Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005; 241: 715-722.
5. Jaffe BM, Donegan WL, Watson F, Spratt JS Jr. Factors influencing survival in patients with untreated hepatic metastases. Surg Gynecol Obstet 1968; 127: 1-11.
6. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
7. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
8. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
9. Memon MA, Beckingham IJ. Surgical resection of colorectal liver metastases. Colorectal Dis 2001; 3: 361-373.
10. Fortner JG, Blumgart LH. A historic perspective of liver surgery for tumors at the end of the millennium. J Am Coll Surg 2001; 193: 210-222.
11. Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 2000; 191: 38-46.
12. Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S et al. Improvement in perioperative outcome after hepatic resection: analysis of 1803 consecutive cases over the past decade. Ann Surg 2002; 236: 397-406.
13. Imamura H, Seyama Y, Kokudo N, Maema A, Sugawara Y, Sano K et al. One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg 2003; 138: 1198-1206.
14. Turunen MJ, Huikuri K, Lempinen M. Results of 32 major hepatic resections for primary and secondary malignancies of the liver. Ann Chir Gynaecol 1986; 75: 209-214.
15. Nagorney DM, van Heerden JA, Ilstrup DM, Adson MA. Primary hepatic malignancy: surgical management and determinants of survival. Surgery 1989; 106: 740-748.
16. Heriot AG, Karanjia ND. A review of techniques for liver resection. Ann R Coll Surg Engl 2002; 84: 371-380.
17. Dimick JB, Cowan JA Jr, Knol JA, Upchurch GR Jr. Hepatic resection in the United States: indications, outcomes, and hospital procedural volumes from a nationally representative database. Arch Surg 2003; 138: 185-191.
18. Poon RT, Fan ST. Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome. Liver Transpl 2004; 10(Suppl 1): S39-S45.
19. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395.
20. Bedogni G, Bellentani S. Fatty liver: how frequent is it and why? Ann Hepatol 2004; 3: 63-65.
21. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988; 27: 142-149.
22. Luyckx FH, Desaive C, Thiry A, Dewe W, Scheen AJ, Gielen JE et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998; 22: 222-226.
23. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-117.
24. Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 1979; 67: 811-816.
25. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-1110.
26. Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis 1986; 8: 283-298.
27. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2002; 17(Suppl): S186-S190.
28. Parikh AA, Gentner B, Wu TT, Curley SA, Ellis LM, Vauthey JN. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg 2003; 7: 1082-1088.
29. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005; 200: 845-853.
30. Couinaud C. Lobes et segments hepatiques. Notes sur l'architecture anatomique et chirurgicale foie. Presse Med 1954; 62: 709-712.
31. Strasberg SM. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg 2005; 12: 351-355.
32. Poon RT, Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK et al. Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. Ann Surg 2004; 240: 698-708.
33. Mentha G, Huber O, Robert J, Klopfenstein C, Egeli R, Rohner A. Elective hepatic resection in the elderly. Br J Surg 1992; 79: 557-559.
34. Kooby DA, Stockman J, Ben-Porat L, Gonen M, Jarnagin WR, Dematteo RP et al. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg 2003; 237: 860-869.
35. Ezaki T, Yukaya H, Ogawa Y. Evaluation of hepatic resection for hepatocellular carcinoma in the elderly. Br J Surg 1987; 74: 471-473.
36. Fan ST, Ng IO, Poon RT, Lo CM, Liu CL, Wong J. Hepatectomy for hepatocellular carcinoma: the surgeon's role in long-term survival. Arch Surg 1999; 134: 1124-1130.
37. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-318.
38. Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001; 234: 507-517.
39. D'Alessandro AM, Kalayoglu M, Sollinger HW, Hoffmann RM, Reed A, Knechtle SJ et al. The predictive value of donor liver biopsies for the development of primary nonfunction after orthotopic liver transplantation. Transplantation 1991; 51: 157-163.
40. Selzner M, Clavien PA. Fatty liver in liver transplantation and surgery. Semin Liver Dis 2001; 21: 105-113.
41. Canelo R, Braun F, Sattler B, Klinge B, Lorf T, Ramadori G et al. Is a fatty liver dangerous for transplantation? Transplant Proc 1999; 31: 414-415.
42. Ploeg RJ, D'Alessandro AM, Knechtle SJ, Stegall MD, Pirsch JD, Hoffmann RM et al. Risk factors for primary dysfunction after liver transplantation - a multivariate analysis. Transplantation 1993; 55: 807-813.
43. Behrns KE, Tsiotos GG, DeSouza NF, Krishna MK, Ludwig J, Nagorney DM. Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg 1998; 2: 292-298.
44. Kooby DA, Fong Y, Suriawinata A, Gonen M, Allen PJ, Klimstra DS et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 2003; 7: 1034-1044.
45. Shimada M, Takenaka K, Fujiwara Y, Gion T, Shirabe K, Yanaga K et al. Risk factors linked to postoperative morbidity in patients with hepatocellular carcinoma. Br J Surg 1998; 85: 195-198.
46. Little SA, Jarnagin WR, DeMatteo RP, Blumgart LH, Fong Y. Diabetes is associated with increased perioperative mortality but equivalent long-term outcome after hepatic resection for colorectal cancer. J Gastrointest Surg 2002; 6: 88-94.
47. Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224: 509-520.
48. Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10: 663-669.
49. Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001; 8: 347-353.
50. Kemeny N, Jarnagin W, Paty P, Gonen M, Schwartz L, Morse M et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 2005; 23: 4888-4896.